MTOR and hepatocellular carcinoma: However, significant benefits of mTOR inhibitors were only observed in patients within Milan criteria (i.e., low-risk patients) in a prospective, randomized, phase 3 clinical trial of sirolimus-based immunosuppression in 525 HCC liver transplant recipients [50].